SCHEMBL20156027

SCHEMBL20156027

CSc1cc(C(F)(F)F)ccc1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
LMNA P02545 3/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 3/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CFTR P13569 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5958718 0.85 RAB9A (0.34) MAPTLMNAL3MBTL1RAB9AALDH1A1
SCHEMBL3277186 0.84 SLC6A2 (0.50) MAPTLMNAL3MBTL1RAB9AALDH1A1
SCHEMBL11896567 0.82 ALDH1A1 (0.53) MAPTLMNAL3MBTL1RAB9AALDH1A1
SCHEMBL28230730 0.81 ADRA2A (0.42) MAPTLMNARAB9AALDH1A1KDM4E
SCHEMBL289622 0.80 NPC1 (0.32) MAPTLMNARAB9AALDH1A1PKM
SCHEMBL1988105 0.78 ADRA2A (0.40) MAPTRAB9AALDH1A1KDM4EATM
SCHEMBL18885104 0.78 PDE2A (0.42) ALDH1A1KDM4ENPSR1GAAKIF11
SCHEMBL27373627 0.78 CES2 (0.46) MAPTLMNARAB9AALDH1A1KDM4E
SCHEMBL8301680 0.76 ALDH1A1 (0.37) RAB9AALDH1A1KDM4EHSD17B10ATM
SCHEMBL8109502 0.76 ADRA2A (0.40) MAPTL3MBTL1RAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MAPT 1236/4885LMNA 2078/4885L3MBTL1 914/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 MAPT 1236/4885LMNA 2078/4885L3MBTL1 914/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 MAPT 1236/4885LMNA 2078/4885L3MBTL1 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.